(5-Ethyl-1,3-oxazol-2-yl)methanamine | 1493849-35-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (5-Ethyl-1,3-oxazol-2-yl)methanamine
• CAS: 1493849-35-6
• 化学式: C₆H₁₀N₂O
• mdl: MFCD21130516
• 分子量: 126.16
• InChiKey: GJSWFDUSJRZKEG-UHFFFAOYSA-N

物化性质

• 沸点：
  185.1±23.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Spirohydantoin compounds and their use as selective androgen receptor modulators
  申请人：NOVARTIS AG

  公开号：US20150299120A1

  公开（公告）日：2015-10-22

  The present invention relates to a compound of formula (I-1) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明涉及一种式子为(I-1)的化合物，其以自由形式或药学上可接受的盐形式存在，其中取代基如规范中定义；以及其制备方法、用作药物的方法和含有该化合物的药物。本发明还提供了一种药理活性剂的组合和制药组合物。
• Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
  申请人：Nerviano Medical Sciences S.R.L.

  公开号：US10280176B2

  公开（公告）日：2019-05-07

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

  本发明公开了说明书中定义的式(Ia)或(Ib)的吡唑-喹唑啉衍生物及其药学上可接受的盐、其制备工艺和包含它们的药物组合物；本发明的化合物在治疗中可用于治疗与蛋白激酶活性紊乱有关的疾病，如癌症。
• PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS
  申请人：Nerviano Medical Sciences, S.R.L.

  公开号：US20170050972A1

  公开（公告）日：2017-02-23

  Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.
• US9637497B2
  申请人：——

  公开号：US9637497B2

  公开（公告）日：2017-05-02
• [EN] COMPOUNDS AND METHODS FOR TREATING NEOPLASIA<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR TRAITEMENT DE LA NÉOPLASIE
  申请人：MEDEXIS S A

  公开号：WO2011029639A2

  公开（公告）日：2011-03-17

  The invention features compounds, pharmaceutical compositions and methods useful for the treatment of neoplasia. In particular embodiments, the compounds of the invention are useful for the treatment of multidrug resistant neoplasia.